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Abstract
Background: Elevated cholesterol levels in children can be a risk factor for cardiovascular diseases in later life. In adults, it
has been shown that blood lipid levels are strongly influenced by polymorphisms in the fatty acid desaturase (FADS) gene
cluster in addition to nutritional and other exogenous and endogenous determinants. Our aim was to investigate whether
lipid levels are determined by the FADS genotype already in children and whether this association interacts with dietary
intake of n-3 fatty acids.
Methods: The analysis was based on data of 2006 children from two German prospective birth cohort studies. Total
cholesterol, HDL, LDL and triglycerides were measured at 10 years of age. Six single nucleotide polymorphisms (SNPs) of the
FADS gene cluster were genotyped. Dietary n-3 fatty acid intake was assessed by food frequency questionnaire. Linear
regression modeling was used to assess the association between lipid levels, n-3 fatty acid intake and FADS genotype.
Results: Individuals carrying the homozygous minor allele had lower levels of total cholesterol [means ratio (MR) ranging
from 0.96 (p = 0.0093) to 0.98 (p = 0.2949), depending on SNPs] and LDL [MR between 0.94 (p = 0.0179) and 0.97 (p = 0.2963)]
compared to homozygous major allele carriers. Carriers of the heterozygous allele showed lower HDL levels [b between
20.04 (p = 0.0074) to 20.01 (p = 0.3318)] and higher triglyceride levels [MR ranging from 1.06 (p = 0.0065) to 1.07
(p = 0.0028)] compared to homozygous major allele carriers. A higher n-3 PUFA intake was associated with higher
concentrations of total cholesterol, LDL, HDL and lower triglyceride levels, but these associations did not interact with the
FADS1 FADS2 genotype.
Conclusion: Total cholesterol, HDL, LDL and triglyceride concentrations may be influenced by the FADS1 FADS2 genotype
already in 10 year old children. Genetically determined blood lipid levels during childhood might differentially predispose
individuals to the development of cardiovascular diseases later in life.
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Introduction
Lipid concentrations in blood are associated with cardiovascular
diseases [1–4]. Elevated cholesterol levels during childhood and
adolescence increases the risk for cardiovascular diseases in
adulthood. Moreover treatments which effectively lower choles-
terol levels early in life have been shown to prevent disease
manifestation in later life [5–7].
Among other factors, dietary polyunsaturated fatty acid (PUFA)
intake can attenuate high blood lipid concentrations [8–10].
In addition to dietary influences, recent genome wide associ-
ation studies have identified several genetic loci that are associated
with blood lipid levels in adults [11–15]. Among the top hits for
the determination of lipid levels are polymorphisms in the fatty
acid desaturase (FADS) gene cluster. Lower total cholesterol [11],
low-density lipoprotein (LDL) [11–13], high-density lipoprotein
(HDL) [13,14] and higher triglyceride levels [14,15] are all
associated with the minor alleles of the tested FADS polymor-
phisms. The genes FADS1 and FADS2, which are both located in
this gene cluster, encode the enzymes delta-5-desaturase and delta-
6-desaturase, which are involved in the conversion of dietary n-3
and n-6 fatty acids to their longer chain metabolites [16].
Polymorphisms in these genes are associated with n-3 and n-6
fatty acid levels in blood and several tissues [17–23]. Carriers of
the minor alleles exhibit increased levels of desaturase substrates
and decreased levels of desaturase products. This trend may be the
result of lower transcription levels or diminished enzyme
conversion rates in individuals carrying the minor alleles [17].
The previously reported strong association of FADS polymor-
phisms with lipid levels in adults makes these genes good
candidates for genetic association studies focused on lipid levels
in children. Given the role of the gene products in the conversion
of dietary fatty acids to biologically important longer chain
polyunsaturated fatty acids, which in turn have been shown to
influence lipid levels, interaction analysis between genetic poly-
morphisms and dietary intake of fatty acids for individual lipid
levels is of interest.
In this study we investigated whether genetic variations of the
FADS gene cluster already pre-determines total cholesterol, HDL,
LDL and triglyceride levels in 10 year old children and whether
genetic variation interacts with dietary intake of n-3 PUFAs to
determine individual blood lipid levels.
Results
Information on lipid concentrations in blood and FADS1 FADS2
genotype was available for 2006 children (1288 (64%) children
from the GINIplus study and 718 (36%) children from the
LISAplus study). Information on n-3 PUFA intake was only
available for 1697 of these children (1100 (65%) children from the
GINIplus study and 597 (35%) children from the LISAplus study).
Basic characteristics of the study population are presented in
Table 1. Total cholesterol, LDL and triglyceride concentrations
were significantly higher in the GINIplus study, whereas HDL
concentrations were higher in the LISAplus study.
The genotype and allele frequencies of the six SNPs which were
included in the analysis are shown in Table 2. There was no
difference in the allele frequency distribution between the
GINIplus and LISAplus studies.
Five of the six SNPs (rs174545, rs174546, rs174556, rs174561
and rs3834458) are in high LD with each other. For these five
SNPs, the pairwise squared correlations r2 ranged from 0.83 to
0.99, and Lewontin’s D’ ranged from 0.98 to 1.
For rs174575, the linkage disequilibrium is lower. The pairwise
correlation r2 for this SNP ranged from 0.49 to 0.66 and
Lewontin’s D’ ranged from 0.77 to 0.96.
Median levels of total cholesterol, HDL, LDL and triglyceride
concentrations, stratified by FADS genotype, are presented in
Table 3. Homozygous minor allele carriers had lower levels of
total cholesterol and LDL compared to homozygous or heterozy-
gous major allele carriers. In contrast, triglyceride concentrations
were higher in minor allele carriers compared to homozygous
major allele carriers. After adjustment for multiple testing
(acorr = 0.025), these associations remained significant for triglyc-
eride levels and LDL (rs174556 and rs174561).
The results of the linear regression models for total cholesterol,
HDL, LDL and triglyceride concentrations, the FADS genotype
and n-3 PUFA intake are presented in Table 4. Adjusted means
ratios for total cholesterol, LDL and triglyceride concentrations
and effect estimates for HDL are shown.
The p-values describing the association between n-3 PUFA
intake and elevated concentrations of total cholesterol [MR = 1.01
for all six SNPs (p-value ranging from 0.0288 to 0.0884)], LDL
[MR from 1.01 (p = 0.1075) to 1.02 (p = 0.0411)], HDL [b= 0.02
for all six SNPs (p-value between 0.0126 and 0.0306)] and reduced
triglyceride levels [MR between 0.97 (p = 0.0219) and 0.98
(p = 0.0841)] were statistically significant. However, after correct-
ing for multiple testing, only five (out of six) SNPs for HDL and
triglyceride levels and rs3834458 remained significant.
Additional analyses showed similar results for the n-3 PUFAs
ALA, EPA, DPA and DHA, which were combined into the total
dietary n-3 PUFA intake (data not shown).
There was no association between dietary n-6 PUFA intake and
lipid levels (data not shown).
Homozygous minor allele carriers had decreased levels of total
cholesterol [MR ranging from 0.96 (p = 0.0093) to 0.98
(p = 0.2949)] and LDL [MR between 0.94 (p = 0.0179) and 0.97
(p = 0.2963)] compared to homozygous major allele carriers. After
correcting for multiple testing (acorr = 0.025), the association
remained significant for rs174556 and rs174561 and total
cholesterol and LDL.
HDL concentrations were reduced in carriers of the heterozy-
gous genotype compared to homozygous major allele carriers [b
between 20.04 (p = 0.0074) to 20.01 (p = 0.3318)]. These
associations remained significant for four SNPs after correction
for multiple testing.
Individuals carrying the heterozygous genotype showed signif-
icantly increased triglyceride levels compared to homozygous
major allele carriers [MR ranging from 1.06 (p = 0.0065) to 1.07
(p = 0.0028)]. These associations remained significant after
correcting for multiple testing. Although homozygous minor allele
carriers also showed increased triglyceride levels, these effects did
not reach statistical significance. Additional analyses restricted to
fasting blood samples did not show substantially different results
and the magnitude of the association between FADS genotype, n-3
PUFA and lipid concentration was similar. However, this result
did not reach statistical significance, likely because of the reduced
sample size (Table S1).
For each model, including the FADS SNP increased the
percentage of explained variance compared to the model without
any SNPs (Table S2). The maximal increase in the explained
variance was 0.71% for the total cholesterol model (1.98% to
2.69%), 1.28% for the LDL model (from 4.21% to 5.49%), 0.96%
for the HDL model (from 7.83% to 8.79%) and 0.48% for the
triglycerides model (from 12.38% to 12.86%). Additional analyses
stratified by study (GINIplus and LISAplus) showed similar results,
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although again, the lack of statistical significance is likely
attributable to the reduced sample size (Figure S1).
There was no significant interaction between n-3 PUFA intake
and FADS1 FADS2 genotype for any of the tested lipid
concentrations (data not shown).
Discussion
The present study investigated the association between n-3
PUFA intake and FADS genotype with total cholesterol, HDL,
LDL and triglyceride concentrations in 10-year-old children from
the GINIplus and LISAplus birth cohort studies.
Although not all associations were statistically significant after
adjustment for multiple testing, in these children, a higher n-3
PUFA intake was associated with higher total cholesterol, HDL
and LDL and lower triglyceride levels. These associations
remained significant after adjustment for multiple testing for
HDL (five out of six tested SNPs) and triglyceride concentrations
(rs3834458).
Minor alleles of FADS1 and FADS2 SNPs were significantly
associated with higher levels of triglycerides and lower levels of
total cholesterol, HDL, and LDL levels. However, not all of these
associations reached statistical significance after correcting for
multiple testing.
Generally, our results on trends in children are in line with
previously published GWA studies that report an association
between the minor allele of the tested FADS variant with lower
total cholesterol [11], LDL [11–13], HDL [13,14] and higher
triglyceride [14,15] concentrations in adults. Although the sample
size of our cohort is relatively large, failure to reach statistical
significance for all SNPs after correcting for multiple testing may
be due to a lack of statistical power and small effect sizes.
Nevertheless, our effect sizes for total cholesterol and triglycerides
are comparable to those reported for adults [11,14]. Bokor et al.
[24] investigated the association between FADS haplotypes and
lipid levels in adolescents, and reported no associations between
any of the haplotypes and total cholesterol, HDL or LDL.
However, the haplotype carrying the minor allele of rs174546 was
significantly associated with higher triglyceride levels and the effect
size reported is similar to that observed in our study.
The lack of statistical significance with respect to triglyceride
levels in homozygous minor allele carriers may be due to the small
size of this group (7% to 12% of the complete sample).
The inclusion of the FADS SNPs to the model lead to an
increase of explained variance ranging from 0.48% for the
triglyceride model to 1.28% for the LDL model, which showed a
similar level as reported by several studies [25].
Table 1. Basic characteristics of the study population.
GINIplus
(n=1288)
LISAplus
(n =718)
Total
(n = 2006) p-value
Median (25%-Qu.,75%-Qu.) or %
Gender [% male] 49.0 55.6 51.3 0.00521
Age [weeks] 531 (526,538) 529 (525,536) 530 (525,537) 0.00722
BMI 17 (16,19) 17 (15,18) 17 (16,19) ,0.00012
Fasting blood samples [%] 16.5 21.9 18.4 0.00321
n-3 PUFA intake [mg/MJ] 0.14 (0.13,0.16) 0.14 (0.13,0.16) 0.14 (0.13,0.16) 0.59502
Total energy intake [MJ] 8237 (6900,9907) 8198 (6654,9906) 8231 (6824,9906) 0.40122
Total cholesterol [mmol/L] 4.81 (4.28,5.39) 4.75 (4.30,5.23) 4.79 (4.28,5.32) 0.04222
HDL [mmol/L] 1.20 (1.02,1.41) 1.33 (1.15,1.50) 1.24 (1.06,1.44) ,0.00012
LDL [mmol/L] 2.14 (1.73,2.58) 2.08 (1.72,2.45) 2.12 (1.72,2.53) 0.02252
Triglyceride [mmol/L] 1.24 (0.94,1.67) 1.11 (0.83,1.58) 1.19 (0.90,1.64) ,0.00012
1p-value derived from Fisher’s exact test.
2p-value derived from Wilcoxon rank sum test.
doi:10.1371/journal.pone.0037780.t001
Table 2. Characteristics of the SNPs in the FADS gene cluster.
SNP Alleles N Number of subjects with
(major/minor) genotype (%) allele (%)
A/a aa Aa AA a A
rs174545 G/C 1829 211 (12%) 793 (43%) 825 (45%) 1215 (33%) 2443 (67%)
rs174546 G/A 1854 211 (11%) 804 (43%) 839 (45%) 1226 (33%) 2482 (67%)
rs174556 G/A 1849 165 (9%) 758 (41%) 926 (50%) 1088 (29%) 2610 (71%)
rs174561 A/G 1867 165 (9%) 766 (41%) 936 (50%) 1096 (29%) 2638 (71%)
rs174575 C/G 1974 139 (7%) 738 (37%) 1097 (56%) 1016 (26%) 2932 (74%)
rs3834458 T/DEL 1971 216 (11%) 855 (43%) 900 (46%) 1287 (33%) 2655 (67%)
doi:10.1371/journal.pone.0037780.t002
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Lipid levels in children are determinants for cardiovascular
diseases in adulthood [5–7]. Analysis of the underlying causes for
disturbances in lipid metabolism during childhood can contribute
to the prevention of cardiovascular diseases later in life. Our study
suggests that the FADS1 FADS2 gene cluster may influence lipid
levels in early life.
The underlying causal biological mechanism between an
individual’s FADS genotype and their lipid concentrations is not
Table 3. Median total cholesterol, HDL, LDL and triglyceride concentrations [mmol/L] in with 25%- and 75%-quantiles stratified by
FADS genotype (A: major allele/ a: minor allele).
Total cholesterol HDL LDL Triglyceride
rs174545
AA 4.81
(4.29,5.34)
1.27
(1.06,1.47)
2.13
(1.74,2.57)
1.14
(0.87,1.57)
Aa 4.77
(4.28,5.30)
1.23
(1.06,1.42)
2.13
(1.74,2.51)
1.23
(0.93,1.67)
aa 4.68
(4.18,5.16)
1.26
(1.09,1.43)
2.01
(1.67,2.47)
1.23
(0.92,1.69)
p-value1 0.1189 0.2246 0.0718 0.0058
rs174546
AA 4.82
(4.29,5.34)
1.27
(1.07,1.47)
2.13
(1.74,2.57)
1.14
(0.88,1.57)
Aa 4.77
(4.28,5.31)
1.23
(1.06,1.42)
2.13
(1.74,2.51)
1.24
(0.94,1.68)
aa 4.66
(4.18,5.15)
1.26
(1.09,1.43)
2.01
(1.67,2.47)
1.22
(0.92,1.68)
p-value1 0.0793 0.1494 0.0701 0.0078
rs174556
AA 4.83
(4.30,5.38)
1.27
(1.07,1.47)
2.14
(1.74,2.58)
1.15
(0.88,1.58)
Aa 4.76
(4.28,5.30)
1.23
(1.06,1.41)
2.12
(1.73,2.49)
1.23
(0.94,1.69)
aa 4.65
(4.18,5.08)
1.25
(1.09,1.43)
1.98
(1.65,2.38)
1.22
(0.90,1.68)
p-value1 0.0263 0.0842 0.0182 0.0071
rs174561
AA 4.83
(4.30,5.38)
1.27
(1.07,1.47)
2.14
(1.74,2.59)
1.15
(0.88,1.58)
Aa 4.76
(4.28,5.29)
1.23
(1.06,1.42)
2.12
(1.73,2.49)
1.23
(0.94,1.69)
aa 4.65
(4.18,5.11)
1.25
(1.09,1.43)
2.00
(1.65,2.38)
1.25
(0.92,1.68)
p-value1 0.0288 0.1042 0.0145 0.0076
rs174575
AA 4.80
(4.28,5.32)
1.26
(1.06,1.46)
2.12
(1.73,2.53)
1.15
(0.88,1.57)
Aa 4.80
(4.31,5.35)
1.23
(1.06,1.43)
2.16
(1.75,2.54)
1.25
(0.93,1.72)
aa 4.63
(4.18,5.08)
1.24
(1.04,1.41)
1.96
(1.68,2.36)
1.24
(0.98,1.70)
p-value1 0.0390 0.3346 0.0325 0.0032
rs3834458
AA 4.81
(4.30,5.35)
1.26
(1.06,1.47)
2.13
(1.73,2.56)
1.15
(0.88,1.58)
Aa 4.79
(4.28,5.33)
1.23
(1.06,1.42)
2.16
(1.75,2.53)
1.24
(0.94,1.68)
aa 4.65
(4.23,5.14)
1.25
(1.06,1.43)
2.01
(1.68,2.40)
1.22
(0.94,1.69)
p-value1 0.0434 0.2505 0.0414 0.0081
1p-value derived from Kruskal-Wallis rank sum test. Significance level after correction for multiple testing: acorr = 0.025. Values reaching significance after adjustment for
multiple testing are highlighted in bold.
doi:10.1371/journal.pone.0037780.t003
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entirely clear. It is likely that the composition of polyunsaturated
fatty acids in human tissues, which has been shown to be highly
associated with the FADS genotype [17], is the direct link between
the observed associations. Tanaka et al. [26] presumed that higher
concentrations of the precursor fatty acids in minor allele carriers
may result in increased membrane fluidity, and thus, in lower
LDL. In addition to altered membrane fluidity, differential
concentrations of long-chain PUFAs (LC-PUFAs) may lead to a
change in the activation of transcription factors such as
peroxisome proliferator activating receptor alpha (PPARA).
Endogenous LC-PUFAs are natural ligands of PPARA [27],
whose activation has been shown to influence the expression of
apo-lipoproteins (e.g. ApoAI, Apo-AII, and ApoCIII) and enzymes
(lipoprotein lipase) that are involved in the metabolism of
lipoprotein particles [28–31].
The effect of FADS genotypes on fatty acid levels, which are also
influenced by nutrition, leads to further interesting questions. One
of which is whether there is a concerted interaction effect between
FADS genotypes and PUFA intake on lipid levels. To date, few
studies have dealt with this issue. Lu et al. [32] reported an
association between FADS genotype and lipid levels, but only in
groups with a high n-3 or n-6 PUFA intake. This result suggests an
interaction between genotype and fatty acid intake, although a
complete interaction analysis was not performed in this study. In
our study, a higher intake of n-3 PUFA was associated with higher
total cholesterol, HDL and LDL levels and lower triglyceride
concentrations, although these effects were not significant after
adjustment for multiple testing. We did not find any association
between lipid levels, FADS genotype and dietary n-6 PUFA intake
(data not shown). In our interaction analysis, we did not find a
modification of the effect of n-3 PUFA intake on lipid
concentrations in blood by the FADS genotype.
Additionally, the number of multiple comparisons has to be
considered. In our manuscript, 24 hypotheses are investigated (6
SNPs and 4 traits). A correction for multiple testing is necessary, if
several independent hypotheses are tested simultaneously. In the
present manuscript, neither the SNPs, nor traits are independent.
A more stringent approach, which would account for the number
of outcome variables, would lead to a corrected alpha level of
0.0063. Taking this alpha level as a basis, the association between
individuals carrying the heterozygous genotype and triglyceride
levels compared to homozygous major allele carriers remains
significant for five out of six SNPs. However, the reported
associations with each of the selected six SNPs with traits were
similar, possibly due to high correlation. A chance finding would
be obvious, if just one of the tested SNPs were highly statistical
significant, where the others were not. This is not the case in our
Table 4. Results of linear regression models for total cholesterol, HDL, LDL and triglyceride concentrations, FADS genotype (A:
major allele/ a: minor allele, reference: homozygous major allele) and n-3 PUFA intake (per IQR increase, IQR (n-3 PUFA) = 0.04 mg/
MJ) adjusted for gender, study centre, age, BMI, fasting status and total dietary energy intake [MJ].
Total cholesterol HDL LDL Triglycerides
MR 95% CI p-value1 Estimate Sd p-value1 MR 95% CI p-value1 MR 95% CI p-value1
rs174545 n= 1532 N= 1531 n= 1531 n = 1531
n-3 PUFA 1.01 (1.00, 1.02) 0.0568 0.02 0.01 0.0193 1.01 (1.00, 1.03) 0.1023 0.98 (0.96, 1.00) 0.0841
Aa (ref AA) 1.00 (0.98, 1.02) 0.8311 20.04 0.02 0.0214 1.01 (0.98, 1.04) 0.6525 1.06 (1.02, 1.11) 0.0063
aa (ref AA) 0.98 (0.95, 1.00) 0.0909 20.01 0.02 0.6368 0.97 (0.92, 1.02) 0.1758 1.05 (0.97, 1.12) 0.2148
rs174546 n= 1554 n= 1553 n= 1553 n = 1553
n-3 PUFA 1.01 (1.00, 1.02) 0.0823 0.02 0.01 0.0147 1.01 (1.00, 1.03) 0.1072 0.98 (0.95, 1.00) 0.0413
Aa (ref AA) 1.00 (0.98, 1.02) 0.9721 20.04 0.02 0.0113 1.01 (0.97, 1.04) 0.7541 1.07 (1.02, 1.11) 0.0048
aa (ref AA) 0.97 (0.95, 1.00) 0.0592 20.01 0.02 0.6663 0.97 (0.92, 1.02) 0.1777 1.03 (0.96, 1.11) 0.3621
rs174556 n= 1548 n= 1547 n= 1547 n = 1547
n-3 PUFA 1.01 (1.00, 1.02) 0.0884 0.02 0.01 0.0173 1.01 (1.00, 1.03) 0.1075 0.98 (0.95, 1.00) 0.0363
Aa (ref AA) 1.00 (0.98, 1.01) 0.6460 20.04 0.02 0.0074 0.99 (0.96, 1.03) 0.7434 1.07 (1.02, 1.12) 0.0035
aa (ref AA) 0.96 (0.93, 0.99) 0.0093 0.00 0.03 0.8902 0.94 (0.88, 0.99) 0.0179 1.02 (0.94, 1.10) 0.6769
rs174561 n= 1564 n= 1563 n= 1563 n = 1563
n-3 PUFA 1.01 (1.00, 1.02) 0.0577 0.02 0.01 0.0306 1.01 (1.00, 1.03) 0.0790 0.98 (0.96, 1.00) 0.0533
Aa (ref AA) 1.00 (0.98, 1.01) 0.7075 20.04 0.02 0.0094 1.00 (0.96, 1.03) 0.8039 1.07 (1.02, 1.11) 0.0041
aa (ref AA) 0.96 (0.93, 0.99) 0.0107 0.00 0.03 0.9700 0.94 (0.89, 0.99) 0.0207 1.02 (0.95, 1.11) 0.5278
rs174575 n= 1662 n= 1661 n= 1661 n = 1661
n-3 PUFA 1.01 (1.00, 1.02) 0.0290 0.02 0.01 0.0140 1.02 (1.00, 1.03) 0.0411 0.97 (0.95, 1.00) 0.0258
Aa (ref AA) 1.01 (1.00, 1.03) 0.1070 20.01 0.01 0.3318 1.03 (0.99, 1.06) 0.1020 1.07 (1.02, 1.11) 0.0028
aa (ref AA) 0.98 (0.95, 1.02) 0.2949 20.01 0.03 0.6907 0.97 (0.91, 1.03) 0.2963 1.07 (0.99, 1.16) 0.0922
rs3834458 n= 1659 n= 1658 n= 1658 n = 1658
n-3 PUFA 1.01 (1.00, 1.02) 0.0288 0.02 0.01 0.0126 1.02 (1.00, 1.03) 0.0422 0.97 (0.95, 1.00) 0.0219
Aa (ref AA) 1.00 (0.98, 1.02) 0.9479 20.03 0.01 0.0324 1.01 (0.98, 1.04) 0.6232 1.06 (1.02, 1.11) 0.0065
aa (ref AA) 0.97 (0.95, 1.00) 0.0704 20.01 0.02 0.6009 0.97 (0.92, 1.01) 0.1674 1.04 (0.98, 1.12) 0.2130
1Significance level after correction for multiple testing: acorr = 0.025. Values reaching significance after adjustment for multiple testing are highlighted in bold.
doi:10.1371/journal.pone.0037780.t004
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analyses. Therefore, we do not consider these results as chance
finding.
Nevertheless, our results suggest that there is an effect of n-3
PUFA intake as well as an effect of FADS genotype on lipid levels,
although these effects do not interact with each other. It is known,
that the conversion rate from dietary PUFA intake to longer chain
metabolites is depending on the FADS genotype [17]. Therefore, it
might be possible that dietary n-3 PUFA intake as well as the
FADS genotype have a linear influence on the endogenous PUFA
levels. This would be in line with the results presented by Molto´-
Puigmartı´ et al. [22]. They reported lower DHA proportions in
plasma phospholipids in women carrying the homozygous minor
allele, but the DHA proportions increased with higher intake of
fatty fish to a similar extent for all genotypes.
To our knowledge, this is the first study which has examined the
complex associations between genetics, diet, and lipid levels in
10 year old children.
In addition to its strength, our study also faces some limitations
which must be considered. Although lipid levels were measured
from blood samples, the dietary fatty acid intake was assessed by a
FFQ. The FFQ used in the present study measured dietary intake
over the past 12 months and was validated for the dietary n-3
PUFA intake. Alternatively, it might be interesting to examine the
association of FADS genes, lipid concentrations and measured fatty
acid blood levels. A further limitation of our study is the low
proportion of fasting blood samples (18.4%). The presented results
were adjusted for fasting status. Additionally, the magnitude of the
association between FADS genotype, n-3 PUFA and lipid
concentration was similar when the sample was restricted to those
with information on fasting blood, although statistical significance
was lacking due to a reduced sample size (Results for triglyceride
levels are presented in Table S1).
In order to increase the power, the two independent studies
GINIplus and LISAplus were analyzed together. Additional
analyses stratified for the GINIplus and LISAplus studies showed
consistent results (Figure S1), except for LDL, although signifi-
cance was missed due to the reduced sample size. This
investigation addressed a complex hypothesis and is based on a
specific data situation: Dietary fatty acid intake was assessed using
a FFQ, which was especially developed and validated for dietary
fatty acid intake in this specific study population [33], blood lipid
levels of total cholesterol, HDL, LDL and triglycerides were
measured and genotyping of six variants of the FADS1 FADS2 gene
cluster was performed. Nevertheless, the results in the two
independent studies GINIplus and LISAplus, which are based
on the same methodology, are similar and our results are
comparable to those reported for adults.
Our study suggests that the FADS1 FADS2 gene cluster may
affect lipid levels already in childhood. Although the explained
variance is low, and can therefore not be used for prevention or
prediction purposes, these results underline the hypothesis that
there is a causal association between dietary n-3 PUFA intake and
lipid levels in children and may help to identify the causal
biological mechanism.
However, further studies are needed to investigate the long-term
effects of the impact of dietary intervention on the development of
cardiovascular diseases, while considering the influence of the
FADS gene cluster.
Materials and Methods
Study population
Data from two ongoing German birth cohort studies were
included in this investigation: the German LISAplus (Life-style
Related Factors on the Immune System and the Development of
Allergies in Childhood PLUS the influence of traffic emissions and
genetics) and GINIplus (German Infant Nutritional Intervention
PLUS environmental and genetic influences on allergy develop-
ment) studies. LISAplus is a population based birth cohort study in
which a total of 3097 neonates were recruited between 1997 and
1999 from the German cities of Munich, Leipzig, Wesel and Bad
Honnef. The participants were not pre-selected based on family
history of allergic diseases [34]. A total of 5991 mothers and their
newborns were recruited from Munich and Wesel into the
GINIplus study between September 1995 and June 1998. Infants
with at least one allergic parent and/or sibling were allocated to
the interventional study arm which investigated the effect of
different hydrolysed formulas consumed during the first year of life
on the development of allergies [35]. All children without a family
history of allergic diseases and children whose parents did not give
consent for the randomized clinical trial were allocated to the non-
interventional arm. Given that the entire current GINIplus study is
composed of both the interventional and non-interventional arm,
this cohort is also population-based. Detailed descriptions of the
LISAplus and GINIplus studies have been published elsewhere
[34–36]).
In both studies only individuals with Caucasian German descent
were included.
For this analysis, only data from the 10 year follow-up is used.
During this follow-up, blood samples were collected and in a
subset of almost 20% of the children fasting blood samples could
be collected.
For both studies, approval by the local Ethics Committees
(Bavarian Board of Physicians, University of Leipzig, Board of
Physicians of North-Rhine-Westphalia) and written consent from
participant’s families were obtained.
Dietary n-3 PUFA intake
A food frequency questionnaire (FFQ) was developed to
measure a child’s usual food and nutrient intake during one year,
and more specifically, to estimate energy, fatty acid and
antioxidant intake at 10 years of age. The FFQ comprised a list
of 82 food items accompanied by several questions about the
preferred fat and energy content of products, preparation
methods, diet and food preferences, buying habits and dietary
supplement use. The consumption frequencies and portion size
estimates were converted to average consumption in grams per
day and linked to the German Nutrient Data Base, version II.3.1
[37]. The design of the FFQ, including the selection of the food
item list, validation, and the calculation of food and nutrient intake
is described in more detail by Stiegler et al. [33].
The intake of n-3 PUFA was calculated by summing a child’s
daily intake of a-linolenic acid (ALA, 18: 3n-3), eicosapentaenoic
acid (EPA, 20: 5n-3), docosapentaenoic acid (DPA, 22: 5n-3) and
docosahexaenoic acid (DHA, 22: 6n-3).
Genotyping
Six single nucleotide polymorphisms (SNPs) in the FADS1
FADS2 gene cluster (rs174545, rs174546, rs174556, rs174561,
rs174575 and rs3834458) were genotyped. Five of these variants
(rs174545, rs174546, rs174556, rs174561 and rs3834458) are in
strong linkage disequilibrium (LD) with each other (r2.0.7,
D’.0.9) [17], and were selected based on previous publications in
adult populations [17,38]. Additionally, we included the rs174575
SNP in order to obtain a better coverage of the FADS gene cluster.
This SNP was selected based on a previous publication in children
[39]. By applying the tagger server program (http://www.
broadinstitute.org/mpg/tagger/) in combination with HapMap
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(http://hapmap.ncbi.nlm.nih.gov/), we were able to tag 27
additional SNPs between base pair positions 61234329 and
61372379 in the FADS1 FADS2 gene cluster using three of our
original SNPs (rs174545, rs174546 and rs174556). The efficiency
was 10.7 fold, however of these new 27 SNPs, rs174561 and
rs3834458 could not be used in the analysis as these are not
included in the HapMap database. Genotyping of SNPs was
conducted using the iPLEX (Sequenom, San Diego, CA, USA)
method by means of matrix assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF MS, Mass Array;
Sequenom) in one laboratory, according to the manufacturer’s
instructions. Standard genotyping quality control included 10%
duplicate and negative samples. The genotyping discordance rate
was below 0.3%.
Measurement of lipids
The measurement of serum lipids and lipoproteins was
performed using homogenous enzymatic colorimetric methods
according to the manufactures instructions (Roche Diagnostics
GmbH Mannheim). All parameters and controls were analysed on
a Modular Analytics System from Roche Diagnostics GmbH
Mannheim.
External controls were used in accordance with the guidelines of
the German Society of Clinical Chemistry and Laboratory
Medicine.
Statistical analysis
Because of the skewed distribution, total cholesterol, LDL and
triglyceride concentrations were naturally log-transformed. After-
wards, linear regression modelling was used to assess the
association between log-transformed total cholesterol, HDL, log-
transformed LDL and log-transformed triglyceride concentrations,
n-3 PUFA intake and FADS genotype. Therefore, for HDL, the
regression coefficient b (Estimate) with standard deviation (Sd) is
shown.
For total cholesterol, LDL and triglyceride, the results are
presented as means ratio (MR) with 95% confidence interval (95%
CI). The MR can be easily calculated for lognormal distributed
variables and is derived by applying the exponential function on
the regression coefficient b (i.e. MR = exp (b)). It describes the
ratio of the mean of the outcome variable in one group compared
to the mean of the outcome variable in the reference group. The
MR can be interpreted as percentage change in the mean of the
outcome variable in one group compared to the reference group
adjusted for confounder variables.
The dietary n-3 PUFA intake was included in the regression
analyses as nutrient density (n-3 PUFA intake divided by total
energy intake). Additionally, the results were adjusted for total
energy intake [40]. In order to compare the effect size of high
(75% quantile) and low (25% quantile) dietary n-3 PUFA intake,
the influence of n-3 PUFA intake is given per interquartile range
increase (IQR (n-3 PUFA) = 0.04 mg/MJ).
All regression models were adjusted for gender, study centre
(Munich, Wesel, Leipzig and Bad Honnef), age, BMI at 10 years
of age and fasting status.
Moreover, in additional analyses, an interaction between n-3
PUFA and FADS genotype (reference: homozygous major allele),
was included in the linear regression models in order to test
whether the effect of dietary n-3 PUFA intake is modified by FADS
variants.
Statistical significance was defined by a two-sided alpha level of
5%. We corrected for multiple testing according to Nyholt [41]. In
brief, this method takes the correlation pattern between the SNPs
into account and reduces the number of variables in a set to the
effective number of variables and provides thereby an estimate of
the number of independent tests.
The alpha level is divided by the number of effective loci (which
was computed as two, based on the number of effective loci of the
six SNPs in the FADS gene cluster), which yields a corrected two-
sided alpha level of 0.025 (5%/2 = 2.5%).
Differences between the GINIplus and LISAplus studies were
tested using Fisher’s exact test or Wilcoxon rank sum test. The
association between lipid concentrations and FADS genotype was
tested using Kruskal-Wallis rank sum test, a nonparametric
method to test whether the median of the lipid concentrations is
different between the FADS genotypes.
Statistical analysis was performed using the statistical software
R, version 2.13.1 (http://www.R-project.org) [42].
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